Thermo Fisher Set to Report Q2 Earnings: What's in the Cards?
TMO readies for second-quarter 2026 earnings, with growth expected across key segments as bioproduction, clinical research and new launches support results.
TMO - Thermo Fisher Scientific Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$585.18
DETAILS
HIGH:
$683.00
LOW:
$490.00
MEDIAN:
$600.00
CONSENSUS:
$585.18
UPSIDE:
9.90%
Stock News
TMO Fairly Valued by DCF at $478
On July 13, 2026, we present a detailed DCF analysis for Thermo Fisher Scientific Inc (TMO), a company currently priced at $527.05. Despite a year-to-date decli
Thermo Fisher Scientific Announces Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on October 15, 2026, to shareholders of record as of September 15, 2026. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world h.
Thermo Fisher Q2 Preview: Buy Before The Recovery
Thermo Fisher Scientific Inc. is down 12.2% YTD, underperforming both the S&P 500 and the healthcare sector. Key risks include NIH funding uncertainty, China weakness, slow organic recovery, and integration risk from the $8.9B Clario acquisition. TMO trades at an 18% discount to its 5-year average P/E, reflecting much of the downside already priced in.
Thermo Fisher Scientific Receives First FBI Approval for Rapid DNA Crime Scene Profiles Eligible for National CODIS Searches
SAN FRANCISCO--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced that the Applied Biosystems™ RapidINTEL™ Plus Cartridge has received approval from the Federal Bureau of Investigation (FBI) National DNA Index System (NDIS) for use with qualifying forensic crime scene samples. The law enforcement milestone makes Thermo Fisher's Rapid DNA workflow on the RapidHIT ID™ System the first eligible to generate DNA profiles that can be searched against the n.
Arcturus Picks Thermo Fisher To Support Cystic Fibrosis Therapy
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is collaborating with Thermo Fisher Scientific Inc. (NYSE:TMO) to support the Phase 3 development and potential commercialization of ARCT-032, the company's investigational messenger RNA therapy for cystic fibrosis.
Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 23, 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2026 before the market opens on Thursday, July 23, 2026, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. The call will be webcast live on the “Investors” section of our website, www.thermofish.
genedrive shares climb 8% on Thermo Fisher pharmacogenetic testing deal
genedrive PLC (AIM:GDR, FRA:D6M) has signed a collaboration agreement with Thermo Fisher Scientific, sending its shares up 8% to 1.4p. The point-of-care pharmacogenetic testing company will develop a high-throughput laboratory test under the deal.
Thermo Fisher Scientific Showcases New Capabilities Across Manufacturing, Clinical Development and AI-Enabled Research at BIO International 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, will showcase new capabilities, strategic investments and initiatives at BIO International 2026 that are helping pharma and biotech customers advance innovation, simplify complex workflows and bring therapies to patients faster. Spanning AI-enabled research, clinical development and advanced manufacturing, these investments reinforce Thermo Fisher's role as a trusted strategic provider of integrated.
West Pharma names former Thermo Fisher executive Lagarde as CEO
West Pharmaceutical said on Monday it appointed former Thermo Fisher Scientific executive Michel Lagarde as its top boss, effective August 31, succeeding longtime chief Eric Green.
Thermo Fisher Scientific Expands Orbitrap Innovation Across Research, Biopharma and Applied Testing at ASMS 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today expanded its suite of Thermo Scientific™ Orbitrap™ mass spectrometry platforms, AI-enabled software and integrated workflows at the American Society for Mass Spectrometry (ASMS) Conference. Across research, biopharma and applied testing, scientists face increasingly complex samples, expanding data sets and greater pressure to deliver confident answers faster. Thermo Fisher helps solve that.
Thermo Fisher (TMO) Surges 6.8%: Is This an Indication of Further Gains?
Thermo Fisher (TMO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Thermo Fisher Scientific Inc (TMO) Stock Up 6.8% and Still Undervalued -- GF Score: 83/100
On May 28, 2026, Thermo Fisher Scientific Inc (TMO) shares rose 6.8% today, now trading at $487.22. The stock's performance remains volatile with a 52-week rang
Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the Thermo Scientific™ Orbitrap™ Tribrid™ Apex and Thermo Scientific™ Orbitrap™ Excedion™ mass spectrometers will be showcased at the American Society for Mass Spectrometry (ASMS) Conference. As scientific discovery expands into more complex applications—from advanced proteomics and multiomics to biologics and genetic medicines—researchers and drug developers face inc.
TMO Fairly Valued by DCF at $478
On May 26, 2026, we present a DCF analysis for Thermo Fisher Scientific Inc (TMO). The stock has experienced a mixed performance recently, with a year-to-date d
Thermo Fisher Scientific Inc. (TMO) Analyst/Investor Day Transcript
Thermo Fisher Scientific Inc. (TMO) Analyst/Investor Day Transcript
Thermo Fisher Scientific Announces Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on July 15, 2026, to shareholders of record as of June 15, 2026. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world healthier.
Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation at 2026 Investor Day
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, hosted its Investor Day today. Chairman and Chief Executive Officer Marc N. Casper and members of the senior leadership team highlighted the company's industry leadership and the essential role of its best-in-class products and services to customers around the world. "Our customers value Thermo Fisher as their trusted partner,” said Marc N. Casper, chairman and chief executive office.
Amazon, McDonald Surge Into Jefferies Top Picks Broadcom as Gets Cut
Jefferies refreshed its Franchise Picks list, adding Amazon (AMZN), AppLovin (APP), Credo Technology (CRDO), McDonald's (MCD), RadNet (RDNT), and Thermo Fisher
Jefferies updates its list of highest-conviction Buy-rated stocks
Jefferies, an investment banking and capital management firm, has updated its ‘Franchise Picks' list, which features the company's highest-conviction ‘Buy' rated stocks.
Price Targets
Thermo Fisher price target lowered to $570 from $575 at Evercore ISI
$570.00
(was $511.31)
Evercore ISI
Thermo Fisher resumed with a Market Perform at Bernstein
$520.00
(was $505.75)
Bernstein
Thermo Fisher initiated with a Neutral at Piper Sandler
$510.00
(was $482.04)
Piper Sandler
HSBC Downgrades Thermo Fisher Scientific (TMO) to Hold
$540.00
(was $482.08)
Sidharth Sahoo
·
HSBC
Thermo Fisher resumed with a Sector Perform at RBC Capital
$490.00
(was $448.21)
RBC Capital
Thermo Fisher price target lowered to $620 from $670 at Morgan Stanley
$620.00
(was $472.23)
Kallum Titchmarsh
·
Morgan Stanley
Thermo Fisher price target lowered to $600 from $700 at Stifel
$600.00
(was $467.47)
Daniel Arias
·
Stifel Nicolaus
Thermo Fisher price target lowered to $639 from $653 at Baird
$639.00
(was $466.70)
Catherine Ramsey Schulte
·
Robert W. Baird
Thermo Fisher price target raised to $615 from $590 at UBS
$615.00
(was $579.86)
UBS
Thermo Fisher Scientific (TMO) PT Lowered to $683 at TD Cowen
$683.00
(was $580.09)
Wells Fargo
Thermo Fisher price target raised to $653 from $645 at Baird
$653.00
(was $583.12)
Robert W. Baird
Thermo Fisher price target raised to $650 from $625 at Barclays
$650.00
(was $592.16)
Barclays
Thermo Fisher price target raised to $700 from $583 at Stifel
$700.00
(was $606.50)
Daniel Arias
·
Stifel Nicolaus
Thermo Fisher price target raised to $650 from $610 at Evercore ISI
$650.00
(was $605.83)
Vijay Kumar
·
Evercore ISI
Thermo Fisher price target raised to $675 from $635 at Wells Fargo
$675.00
(was $571.99)
Wells Fargo
Thermo Fisher initiated with a Buy at Goldman Sachs
$685.00
(was $568.21)
Evie Koslosky
·
Goldman Sachs
Thermo Fisher upgraded to Overweight from Sector Weight at KeyBanc
$750.00
(was $572.77)
Paul Knight
·
KeyBanc
Thermo Fisher price target raised to $610 from $580 at Argus
$610.00
(was $570.82)
Argus Research
Thermo Fisher price target raised to $656 from $560 at Morgan Stanley
$656.00
(was $563.28)
Morgan Stanley
Thermo Fisher price target raised to $590 from $500 at UBS
$590.00
(was $571.67)
UBS